참고문헌
- Esserman L, Yau C. Rethinking the standard for ductal carcinoma in situ treatment. JAMA Oncol 2015;1:881-883 https://doi.org/10.1001/jamaoncol.2015.2607
- Korean Breast Cancer Society. Breast cancer facts & figures 2020. Seoul: Korean Breast Cancer Society, 2020:8-9
- Cady B. How to prevent invasive breast cancer: detect and excise duct carcinoma in situ. J Surg Oncol 1998;69:60-62 https://doi.org/10.1002/(SICI)1096-9098(199810)69:2<60::AID-JSO2>3.0.CO;2-3
- Cowell CF, Weigelt B, Sakr RA, Ng CK, Hicks J, King TA, et al. Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol 2013;7:859-869 https://doi.org/10.1016/j.molonc.2013.07.005
- Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, et al. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study. Eur J Cancer 2015;51:1497-1510 https://doi.org/10.1016/j.ejca.2015.05.008
- Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, et al. Addressing overtreatment of screen detected DCIS; the LORIS trial. Eur J Cancer 2015;51:2296-2303 https://doi.org/10.1016/j.ejca.2015.07.017
- Hwang ES, Hyslop T, Lynch T, Frank E, Pinto D, Basila D, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open 2019;9:e026797
- Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology 2011;260:119-128 https://doi.org/10.1148/radiol.11102368
- Greenwood HI, Wilmes LJ, Kelil T, Joe BN. Role of breast MRI in the evaluation and detection of DCIS: opportunities and challenges. J Magn Reson Imaging 2020;52:697-709 https://doi.org/10.1002/jmri.26985
- Alic L, Niessen WJ, Veenland JF. Quantification of heterogeneity as a biomarker in tumor imaging: a systematic review. PLoS One 2014;9:e110300
- Chou SS, Gombos EC, Chikarmane SA, Giess CS, Jayender J. Computer-aided heterogeneity analysis in breast MR imaging assessment of ductal carcinoma in situ: correlating histologic grade and receptor status. J Magn Reson Imaging 2017;46:1748-1759 https://doi.org/10.1002/jmri.25712
- Ko ES, Kim JH, Lim Y, Han BK, Cho EY, Nam SJ. Assessment of invasive breast cancer heterogeneity using whole-tumor magnetic resonance imaging texture analysis: correlations with detailed pathological findings. Medicine (Baltimore) 2016;95:e2453
- Chang RF, Chen HH, Chang YC, Huang CS, Chen JH, Lo CM. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI. Magn Reson Imaging 2016;34:809-819 https://doi.org/10.1016/j.mri.2016.03.001
- Sutton EJ, Oh JH, Dashevsky BZ, Veeraraghavan H, Apte AP, Thakur SB, et al. Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay. J Magn Reson Imaging 2015;42:1398-1406 https://doi.org/10.1002/jmri.24890
- Lee SH, Park H, Ko ES. Radiomics in breast imaging from techniques to clinical applications: a review. Korean J Radiol 2020;21:779-792 https://doi.org/10.3348/kjr.2019.0855
- Li J, Song Y, Xu S, Wang J, Huang H, Ma W, et al. Predicting underestimation of ductal carcinoma in situ: a comparison between radiomics and conventional approaches. Int J Comput Assist Radiol Surg 2019;14:709-721 https://doi.org/10.1007/s11548-018-1900-x
- Hou R, Grimm LJ, Mazurowski MA, Marks JR, King LM, Maley CC, et al. Prediction of upstaging in ductal carcinoma in situ based on mammographic radiomic features. Radiology 2022;303:54-62 https://doi.org/10.1148/radiol.210407
- Hong M, Fan S, Yu Z, Gao C, Fang Z, Du L, et al. Evaluating upstaging in ductal carcinoma in situ using preoperative MRI-based radiomics. J Magn Reson Imaging 2023;58:454-463 https://doi.org/10.1002/jmri.28539
- Lee HJ, Park JH, Nguyen AT, Do LN, Park MH, Lee JS, et al. Prediction of the histologic upgrade of ductal carcinoma in situ using a combined radiomics and machine learning approach based on breast dynamic contrast-enhanced magnetic resonance imaging. Front Oncol 2022;12:1032809
- Wu Z, Lin Q, Wang H, Wang G, Fu G, Bian T. An MRI-based radiomics nomogram to distinguish ductal carcinoma in situ with microinvasion from ductal carcinoma in situ of breast cancer. Acad Radiol 2023;30 Suppl 2:S71-S81 https://doi.org/10.1016/j.acra.2023.03.038
- Mann RM, Mus RD, van Zelst J, Geppert C, Karssemeijer N, Platel B. A novel approach to contrast-enhanced breast magnetic resonance imaging for screening: high-resolution ultrafast dynamic imaging. Invest Radiol 2014;49:579-585 https://doi.org/10.1097/RLI.0000000000000057
- Mus RD, Borelli C, Bult P, Weiland E, Karssemeijer N, Barentsz JO, et al. Time to enhancement derived from ultrafast breast MRI as a novel parameter to discriminate benign from malignant breast lesions. Eur J Radiol 2017;89:90-96 https://doi.org/10.1016/j.ejrad.2017.01.020
- Kim SY, Cho N, Choi Y, Shin SU, Kim ES, Lee SH, et al. Ultrafast dynamic contrast-enhanced breast MRI: lesion conspicuity and size assessment according to background parenchymal enhancement. Korean J Radiol 2020;21:561-571 https://doi.org/10.3348/kjr.2019.0567
- Goto M, Sakai K, Yokota H, Kiba M, Yoshida M, Imai H, et al. Diagnostic performance of initial enhancement analysis using ultra-fast dynamic contrast-enhanced MRI for breast lesions. Eur Radiol 2019;29:1164-1174 https://doi.org/10.1007/s00330-018-5643-4
- Heacock L, Lewin AA, Gao Y, Babb JS, Heller SL, Melsaether AN, et al. Feasibility analysis of early temporal kinetics as a surrogate marker for breast tumor type, grade, and aggressiveness. J Magn Reson Imaging 2018;47:1692-1700 https://doi.org/10.1002/jmri.25897
- Shin SU, Cho N, Kim SY, Lee SH, Chang JM, Moon WK. Time-to-enhancement at ultrafast breast DCE-MRI: potential imaging biomarker of tumour aggressiveness. Eur Radiol 2020;30:4058-4068 https://doi.org/10.1007/s00330-020-06693-0
- American College of Radiology. ACR BI-RADS(R) Atlas. Breast Imaging Reporting and Data System. 5th ed. Reston: American College of Radiology, 2013
- van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res 2017;77:e104-e107 https://doi.org/10.1158/0008-5472.CAN-17-0339
- Lamb LR, Lehman CD, Oseni TO, Bahl M. Ductal carcinoma in situ (DCIS) at breast MRI: predictors of upgrade to invasive carcinoma. Acad Radiol 2020;27:1394-1399 https://doi.org/10.1016/j.acra.2019.09.025
- Heo S, Park AY, Jung HK, Ko KH, Kim Y, Koh J. The usefulness of ultrafast MRI evaluation for predicting histologic upgrade of ductal carcinoma in situ. Eur J Radiol 2021;136:109519
- El Hage Chehade H, Headon H, Wazir U, Abtar H, Kasem A, Mokbel K. Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis. Am J Surg 2017;213:171-180 https://doi.org/10.1016/j.amjsurg.2016.04.019
- Onishi N, Sadinski M, Hughes MC, Ko ES, Gibbs P, Gallagher KM, et al. Ultrafast dynamic contrast-enhanced breast MRI may generate prognostic imaging markers of breast cancer. Breast Cancer Res 2020;22:58
- Miceli R, Gao Y, Qian K, Heller SL. Predicting upgrade of ductal carcinoma in situ to invasive breast cancer at surgery with ultrafast imaging. AJR Am J Roentgenol 2023;221:34-43 https://doi.org/10.2214/AJR.22.28698
- Gilles R, Zafrani B, Guinebretiere JM, Meunier M, Lucidarme O, Tardivon AA, et al. Ductal carcinoma in situ: MR imaging-histopathologic correlation. Radiology 1995;196:415-419 https://doi.org/10.1148/radiology.196.2.7617854
- Hulka CA, Edmister WB, Smith BL, Tan L, Sgroi DC, Campbell T, et al. Dynamic echo-planar imaging of the breast: experience in diagnosing breast carcinoma and correlation with tumor angiogenesis. Radiology 1997;205:837-842 https://doi.org/10.1148/radiology.205.3.9393545
- Oshida K, Nagashima T, Ueda T, Yagata H, Tanabe N, Nakano S, et al. Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography. Eur Radiol 2005;15:1353-1360 https://doi.org/10.1007/s00330-005-2661-9
- Mori N, Abe H, Mugikura S, Takasawa C, Sato S, Miyashita M, et al. Ultrafast dynamic contrast-enhanced breast MRI: kinetic curve assessment using empirical mathematical model validated with histological microvessel density. Acad Radiol 2019;26:e141-e149 https://doi.org/10.1016/j.acra.2018.08.016
- Bluff JE, Menakuru SR, Cross SS, Higham SE, Balasubramanian SP, Brown NJ, et al. Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. Br J Cancer 2009;101:666-672 https://doi.org/10.1038/sj.bjc.6605196
- Vincent-Salomon A, Lucchesi C, Gruel N, Raynal V, Pierron G, Goudefroye R, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008;14:1956-1965 https://doi.org/10.1158/1078-0432.CCR-07-1465
- Sinha VC, Piwnica-Worms H. Intratumoral heterogeneity in ductal carcinoma in situ: chaos and consequence. J Mammary Gland Biol Neoplasia 2018;23:191-205 https://doi.org/10.1007/s10911-018-9410-6